Leerink Partnrs Has Negative Outlook of Penumbra Q1 Earnings

Penumbra, Inc. (NYSE:PEN) – Research analysts at Leerink Partnrs dropped their Q1 2025 earnings estimates for shares of Penumbra in a research report issued on Tuesday, February 18th. Leerink Partnrs analyst M. Kratky now anticipates that the company will earn $0.69 per share for the quarter, down from their previous estimate of $0.83. The consensus estimate for Penumbra’s current full-year earnings is $3.86 per share. Leerink Partnrs also issued estimates for Penumbra’s Q2 2025 earnings at $0.83 EPS, FY2025 earnings at $3.61 EPS and FY2026 earnings at $5.54 EPS.

Penumbra (NYSE:PEN) last issued its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.09. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The firm had revenue of $315.52 million for the quarter, compared to analysts’ expectations of $311.63 million.

Several other equities research analysts have also issued reports on the stock. StockNews.com raised shares of Penumbra from a “hold” rating to a “buy” rating in a report on Thursday. JPMorgan Chase & Co. boosted their price target on shares of Penumbra from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Wednesday. Piper Sandler reaffirmed an “overweight” rating and set a $330.00 price objective (up from $250.00) on shares of Penumbra in a research note on Wednesday. Morgan Stanley lifted their price objective on shares of Penumbra from $240.00 to $260.00 and gave the stock an “equal weight” rating in a research note on Wednesday. Finally, Citigroup boosted their target price on shares of Penumbra from $220.00 to $245.00 and gave the company a “neutral” rating in a research note on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Penumbra has an average rating of “Moderate Buy” and a consensus price target of $292.64.

Penumbra Price Performance

Shares of NYSE:PEN opened at $302.82 on Friday. The firm’s 50 day moving average price is $258.16 and its 200-day moving average price is $227.04. Penumbra has a twelve month low of $148.00 and a twelve month high of $310.00. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $11.66 billion, a PE ratio of 890.64, a price-to-earnings-growth ratio of 2.23 and a beta of 0.53.

Institutional Trading of Penumbra

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Quadrant Capital Group LLC boosted its stake in shares of Penumbra by 6.6% in the 4th quarter. Quadrant Capital Group LLC now owns 632 shares of the company’s stock valued at $150,000 after buying an additional 39 shares during the period. Pallas Capital Advisors LLC boosted its stake in shares of Penumbra by 3.8% in the 4th quarter. Pallas Capital Advisors LLC now owns 1,108 shares of the company’s stock valued at $263,000 after buying an additional 41 shares during the period. Advisors Asset Management Inc. boosted its stake in shares of Penumbra by 11.5% in the 3rd quarter. Advisors Asset Management Inc. now owns 416 shares of the company’s stock valued at $81,000 after buying an additional 43 shares during the period. Baker Avenue Asset Management LP boosted its stake in shares of Penumbra by 1.6% in the 4th quarter. Baker Avenue Asset Management LP now owns 3,330 shares of the company’s stock valued at $791,000 after buying an additional 53 shares during the period. Finally, Pacer Advisors Inc. boosted its stake in shares of Penumbra by 1.0% in the 4th quarter. Pacer Advisors Inc. now owns 5,721 shares of the company’s stock valued at $1,359,000 after buying an additional 57 shares during the period. 88.88% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Penumbra news, EVP Johanna Roberts sold 600 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $244.49, for a total value of $146,694.00. Following the completion of the sale, the executive vice president now directly owns 63,444 shares of the company’s stock, valued at $15,511,423.56. This trade represents a 0.94 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Lambert Shiu sold 654 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $243.01, for a total value of $158,928.54. Following the sale, the chief accounting officer now directly owns 20,028 shares of the company’s stock, valued at $4,867,004.28. The trade was a 3.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 18,219 shares of company stock valued at $4,426,439 in the last three months. 5.00% of the stock is currently owned by insiders.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.